Florida, USA-based central nervous system (CNS) specialist Relmada Therapeutics (Nasdaq: RLMD) has announced positive results from a late-stage trial of REL-1017.
The novel NMDA receptor channel blocker is in development for the adjunctive treatment of major depressive disorder (MDD).
REL-1017 works by specifically targeting hyperactive channels while maintaining other key processes in the brain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze